TABLE 2.

Drug susceptibilities of HCMV strains resistant to BDCRB and maribavir

Compound	IC50 (μM) in plaque reduction against the following virusesa:				IC90 (μM) in yield reduction against the following virusesb:
	Towne	D10	r56	C4	AD169	2916
853	24 ± 2	56 ± 1*c	51 ± 3*	56 ± 2*	NDd	ND
1049	0.61 ± 0.10	4.6 ± 0.3*	5.3 ± 0.4*	25 ± 5*	ND	ND
1311	0.66 ± 0.42	0.54 ± 0.16	0.81 ± 0.08	0.95 ± 0.18	0.82 ± 0.10	0.70 ± 0.18
GCV	13.3 ± 1.5	12.7 ± 1.2	13.3 ± 0.6	12.0 ± 5.0	1.2 ± 0.4	1.5 ± 0.3
BDCRB	1.0 ± 0.1	11.8 ± 0.8*	8.8 ± 0.7*	37.7 ± 2.5*	0.36 ± 0.12	0.38 ± 0.05
Maribavir	ND	ND	ND	ND	0.19 ± 0.09	57 ± 3*

^aInhibition of HCMV plaque formation was measured by using at least six drug concentrations ranging from 100 to 0.05 μM. Data are presented as the means±SDs of IC₅₀s determined in at least triplicate. HCMV strains D10, r56, and C4 were derived from Towne (wild-type strain) (described in references 24 and 45). D10 bears a mutation in UL89 (D344E), r56 contains a mutation in UL56 (Q204R), and C4 has both mutations.

^bInhibition of HCMV titer production was measured at eight drug concentrations ranging from 100 to 0.05 μM. Data are presented as the means±SDs of IC₉₀s determined in at least quadruplicate. HCMV strain 2916^r was derived from AD169 (wild-type) (described in reference 6). Strain 2916^r contains a mutation in UL97 (I397R).

^c*, P < 0.005 as determined by the Student's t test function of Microsoft Excel.

^dND, not determined.